X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.biospace.com/article/releases/poxel-announces-product-launch-in-japan-for-twymeeg-as-treatment-for-type-2-diabetes/?s=71
https://endpts.com/vivek-ramaswamys-metavant-hits-a-brick-wall-abandoning-a-lead-program-for-diabetes-and-theres-nothing-visible-left-to-see-here/
https://www.fiercebiotech.com/biotech/poxel-posts-phase-3-diabetes-data-ahead-approval-decision
https://www.businesswire.com/news/home/20200915006034/en/Poxel-Reports-Financial-Results-for-First-Half-2020-and-Provides-a-Corporate-Update
https://www.biospace.com/article/releases/poxel-and-sumitomo-dainippon-pharma-announce-second-positive-top-line-results-for-imeglimin-phase-3-trial-times-3-in-japan-for-the-treatment-of-type-2-diabetes-/
Market Place
Share 
